WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND...
WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (œPrelude or the œCompany), a clinical-stage precision oncology company, today announced a...
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (œPrelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical...